Research graph
References from Implementation of guideline-directed cardioprotective therapy in patients living with type 2 diabetes in outpatient cardiology ambulatory setting: the Italian CardioMET registry. Local targets link to admitted publications; unresolved targets remain external evidence.
The lancet commission on diabetes: using data to transform diabetes care and patient lives
10.1016/s0140-6736(20)32374-6 · 2020 · External reference
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
10.1016/s0140-6736(10)60484-9 · 2010 · External reference
Association of cardiometabolic multimorbidity with mortality
10.1001/jama.2015.7008 · 2015 · External reference
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes
10.1093/eurheartj/ehad192 · 2023 · External reference
Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a diabetes care editors' Expert forum
10.2337/dci17-0057 · 2018 · External reference
Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials
10.1093/eurheartj/ehaa082 · 2020 · External reference
Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis
10.1001/jamacardio.2020.4511 · 2021 · External reference
10-year cardiovascular risk estimation in type 2 diabetes in Europe
10.1093/eurheartj/ehad260 · 2023 · External reference
CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries
10.1186/s12933-021-01344-0 · 2021 · External reference
World medical association declaration of helsinki: ethical principles for medical research involving human subjects
10.1001/jama.2013.281053 · 2013 · External reference
Effects of semaglutide on mortality, cardiovascular, and kidney outcomes across the cardio-kidney-metabolic continuum: a systematic review and meta-analysis
10.1186/s12933-026-03215-y · 2026 · External reference
Effects of dapagliflozin on mortality across the spectrum of cardiovascular-kidney-metabolic syndrome: a meta-analysis
10.1016/j.numecd.2025.104366 · 2026 · External reference
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
10.1016/s2213-8587(24)00155-4 · 2024 · External reference
Cardiovascular disease and risk management: standards of care in diabetes—2026
2025 · External reference
Real-world prescriptions of GLP-1RAs and SGLT2is in type 2 diabetes prioritise BMI and age over cardiorenal risk: a machine learning-based large cohort analysis
10.1186/s40842-025-00251-7 · 2025 · External reference
CAPTURE: a cross-sectional study on the prevalence of cardiovascular disease in adults with type 2 diabetes in Italy
10.1016/j.numecd.2022.01.026 · 2022 · External reference
Dapagliflozin and cardiovascular outcomes in type 2 diabetes
10.1056/nejmoa1812389 · 2019 · External reference
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
10.1016/s0140-6736(19)31149-3 · 2019 · External reference
Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis
10.1161/circulationaha.124.071689 · 2024 · External reference
Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study
10.1016/s2666-7568(23)00164-2 · 2023 · External reference
Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a Danish nationwide cohort study
10.1186/s12933-022-01713-3 · 2022 · External reference
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
10.1056/nejmoa1504720 · 2015 · External reference
Liraglutide and cardiovascular outcomes in type 2 diabetes
10.1056/nejmoa1603827 · 2016 · External reference
Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: an NCDR® Research to practice project
10.1177/2047487317729252 · 2017 · External reference
Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men
10.1111/dom.13876 · 2020 · External reference
Effects of Liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial
10.1001/jama.2016.10260 · 2016 · External reference
Dapagliflozin in patients with chronic kidney disease
10.1056/nejmoa2024816 · 2020 · External reference
Empagliflozin in patients with chronic kidney disease
10.1056/nejmoa2204233 · 2023 · External reference
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
10.1056/nejmoa1811744 · 2019 · External reference
Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes
10.1056/nejmoa2403347 · 2024 · External reference
2026 AHA/ACC/ADA/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-Kidney-Metabolic Syndrome: a report of the American college of Cardiology/American heart association joint committee on clinical practice guidelines
10.1161/cir.0000000000001453 · 2026 · External reference
